Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 17 dagu; poliovirus, quantity: 20 dagu; poliovirus, quantity: 5 dagu - injection, suspension - excipient ingredients: sodium hydroxide; hydrochloric acid; formaldehyde solution; phenoxyethanol; glucose monohydrate; purified water; polysorbate 80; ascorbic acid; sodium chloride; aminobenzoic acid; adenosine phosphate; dl-alpha-tocopheryl phosphate disodium; magnesium sulfate; monobasic potassium phosphate; deoxyribose; calcium chloride dihydrate; iron trinitrate; potassium chloride; magnesium sulfate heptahydrate; potassium nitrate; sodium selenite; monobasic sodium phosphate; dibasic sodium phosphate heptahydrate; adenine sulfate; adenosine triphosphate disodium; cholesterol; glutathione; guanine hydrochloride; hypoxanthine; phenolsulfonphthalein; ribose; sodium acetate; thymine; uracil; xanthine; sodium pyruvate; dl-alanine; arginine hydrochloride; dl-aspartic acid; cysteine hydrochloride; cystine dihydrochloride; dl-glutamic acid; glutamine; glycine; histidine hydrochloride; hydroxyproline; isoleucine; asparagine; dl-leucine; lysine hydrochloride; dl-methionine; dl-phenylalanine; proline; dl-serine; - ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. ipol should be offered to patients who have refused opv or in whom opv is contraindicated. ipol is also indicated for: 1) the primary vaccination of immunocompromised individuals of all ages, and household contacts of such individuals (when vaccination is indicated); (2) unvaccinated or inadequately vaccinated(*) adults, particularly if at increased risk of exposure to live polio virus, including: - travellers to areas or countries where poliomyelitis is epidemic or endemic: - laboratory workers handling specimens which may contain polio virus; - health care workers in close contact with patients who may be excreting polioviruses. (*) such as those who may not have completed a primary series of vaccination or not received a booster dose since infancy. idications as at 9 june 2003: ipol is indicated for active immunisation of infants, children and adults for the prevention of poliomyelitis. recommen

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - poliovirus, quantity: 26 dagu; poliovirus, quantity: 7 dagu; pertactin, quantity: 3 microgram; tetanus toxoid, quantity: 20 iu; diphtheria toxoid, quantity: 2 iu; pertussis toxoid, quantity: 2.5 microgram; pertussis filamentous haemagglutinin, quantity: 5 microgram; pertussis fimbriae 2 + 3, quantity: 5 microgram; poliovirus, quantity: 29 dagu - injection, suspension - excipient ingredients: aluminium phosphate; formaldehyde; polysorbate 80; neomycin; water for injections; phenoxyethanol; streptomycin sulfate; polymyxin b sulfate; glutaral; ethanol - adacel polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation.,children 4-6 years of age should have already received four doses of dtpa and ipv or opv.,adacel polio is not intended for primary immunisation.,adacel polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus.,the use of adacel polio should be determined on the basis of official recommendations. for further information, refer to the current immunisation handbook.

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus polio type ii, strain p712, 2ab >= 100000 ccid50/0,1 ml - oral suspension - poliomyelitis virus - poliomyelitis oral, monovalent, live attenuated

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline biologicals sa-nv - virus polio type i, strain lsc, 2ab >= 1000000 ccid50/0,1 ml; virus polio type iii, strain leon 12a, 1b >= 600000 ccid50/0,1 ml - oral suspension - poliomyelitis virus - poliomyelitis oral, bivalent, live attenuated

Kenya - English - Pharmacy and Poisons Board

glaxosmithkline pharmaceutical kenya limited p.o. box 78392 - 00507, nairobi, kenya - virus polio type 1, strain lsc, 2ab; virus polio… - oral suspension - virus polio type 1, strain lsc, 2ab… - poliomyelitis oral bivalent live attenuated

Kenya - English - Pharmacy and Poisons Board

china sinopharm international corporation… 4, huixindongjie, chaoyang district, beijing - virus strain polio virus seed (sabin strain) type… - oral drops - each dose of 2 drops (0.1ml) contains polio virus… - poliomyelitis oral bivalent live attenuated

Ireland - English - HPRA (Health Products Regulatory Authority)

ashford pharmaceuticals limited - poliomyelitis vaccine -

Kenya - English - Pharmacy and Poisons Board

sanofi pasteur s.a. 2 avenue pont pasteur 69007 lyon - poliovirus# type 1 mahoney strain (inactivated) … - suspension for injection - one dose (0.5 ml) contains: poliovirus# type 1… - viral vaccines: poliomyelitis vaccines

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: faberco life sciences inc.; distributor: faberco life sciences inc. - inactivated poliomyelitis vaccine (types 1, 2, and 3) - suspension for injection (im/sc) - formulation: each dose (0.5 ml) contains: inactivated poliovirus type 1, mahoney strain*40 d antigen units inactivated poliovirus type 2, mef-1 strain* 8 d antigen units inactivated poliovirus type 3, saukett strain* 32 d antigen units *cultivated on vero cells

Canada - English - Health Canada

aventis pasteur limited - poliovirus vaccine live orl-trival human type-1; poliovirus vaccine live orl-trival human type-2; poliovirus vaccine live orl-trival human type-3 - suspension - 1000000unit; 100000unit; 300000unit - poliovirus vaccine live orl-trival human type-1 1000000unit; poliovirus vaccine live orl-trival human type-2 100000unit; poliovirus vaccine live orl-trival human type-3 300000unit - vaccines